Research has shown that the infiltration of CD200 + cytotoxic T cells in malignant tumors such as melanoma and esophageal cancer can help improve the patient response rate to PD-1/PD-L1 therapy and prolong survival. This evidence concerns the gene CD274 and esophageal cancer.